Evidence map›Paper›PMID 41724331›Full record

ReviewAdvanced drug delivery reviews2026

Gas entrapping materials for damage control.

Paula K N Alves, Ian C Sutton, James D Byrne, Leo E Otterbein

Abstract readReview
In one paragraph

Review in Advanced drug delivery reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Paula K N AlvesDepartment of Surgery, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.
Ian C SuttonDepartment of Radiation Oncology, University of Iowa, Iowa City, IA 52242, USA.
James D ByrneDepartment of Radiation Oncology, University of Iowa, Iowa City, IA 52242, USA. Electronic address: james-byrne@uiowa.edu.
Leo E OtterbeinDepartment of Surgery, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA. Electronic address: lotterbe@bidmc.harvard.edu.

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Michael J Goodheart · 2000 to 2026
$70.0M
Early-Stage Preclinical Validation of Carbon Monoxide Prodrugs for Acute Kidney InjuryR01DK128823 · NIDDK · GEORGIA STATE UNIVERSITY · PI LEO E OTTERBEIN, Binghe Wang · 2022 to 2026
$3.5M
Novel extremophile-inspired radioprotectantsDP2CA301081 · NCI · UNIVERSITY OF IOWA · PI BYRNE, JAMES DONALD · 2024 to 2024
$1.4M
Exploiting Carbon Monoxide Biofoams to Radio-Sensitize Rectal Cancer Cells While Protecting Normal BowelK08CA276908 · NCI · UNIVERSITY OF IOWA · PI James Donald Byrne · 2023 to 2026
$1.0M
Novel materials for the prevention of PTOAR01AR085602 · NIAMS · UNIVERSITY OF IOWA · PI James Donald Byrne, Mitchell Carl Coleman · 2026 to 2026
$661k
Department of Defense HT9425-23-1-1052Department of Defense HT9425-24-1-0769NCI NIH HHS DP2 CA301081NCI NIH HHS K08 CA276908NCI NIH HHS K08CA276908, DP2CA301081NCI NIH HHS P30 CA086862NCI NIH HHS P30CA086862NIAMS NIH HHS R01 AR085602NIDDK NIH HHS R01 DK128823the American Cancer Society IRG-21-141-46the Holden Comprehensive Cancer Center at the University of Iowa, R01 DK128823-01A1
6 · The paper itself

Abstract

Gasotransmitters, including nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H₂S), are small endogenously produced signaling molecules that regulate critical intra- and intercellular processes. These gases modulate ion channel activity, gene expression, redox balance, and mitochondrial bioenergetics, while influencing cardiovascular, immune, and nervous system functions. Despite their toxicity at high concentrations, controlled exogenous administration of gasotransmitters has enormous therapeutic potential in conditions such as cancer, cardiovascular disease, sepsis, trauma, and brain injury. A central challenge in translating these molecules into clinical use lies in achieving safe, targeted and tunable delivery. Traditional inhalation methods have evolved with advances in medicinal chemistry, and bioengineering, enabling formulations for oral, parenteral, and localized delivery that exploit the gases' ability to freely diffuse across membranes. This review summarizes current strategies for delivering NO, CO, and H₂S using hydrogels, foams, and solid formulations across skin and gut barrier sites. We discuss the mechanisms governing gasotransmitter activity, factors affecting tissue distribution and reactivity, and the potential clinical utility of these delivery approaches. By highlighting recent preclinical and clinical studies, we provide a framework for optimizing gasotransmitter administration, dosage, and specificity, emphasizing their translational relevance as therapeutic agents.

Indexed as

Carbon MonoxideDrug Delivery SystemsGasotransmittersHydrogen SulfideNitric OxideAnimalsHumansCarbon MonoxideGasotransmittersHydrogen SulfideNitric OxideCarbon monoxideGas deliveryGas entrapping materialsGasotransmittersHydrogen sulfideNitric oxide

Identifiers

PMID41724331
PMCPMC13580872

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.